261 related articles for article (PubMed ID: 28696366)
1. Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma.
Cruickshanks N; Zhang Y; Yuan F; Pahuski M; Gibert M; Abounader R
Cancers (Basel); 2017 Jul; 9(7):. PubMed ID: 28696366
[TBL] [Abstract][Full Text] [Related]
2. Aberrant
Al-Ghabkari A; Huang B; Park M
Cells; 2024 Jan; 13(3):. PubMed ID: 38334610
[TBL] [Abstract][Full Text] [Related]
3. Targeting MET for glioma therapy.
Awad AJ; Burns TC; Zhang Y; Abounader R
Neurosurg Focus; 2014 Dec; 37(6):E10. PubMed ID: 25434379
[TBL] [Abstract][Full Text] [Related]
4. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review).
Moriyama T; Kataoka H; Koono M; Wakisaka S
Int J Mol Med; 1999 May; 3(5):531-6. PubMed ID: 10202187
[TBL] [Abstract][Full Text] [Related]
5. Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling.
Lee JK; Joo KM; Lee J; Yoon Y; Nam DH
Onco Targets Ther; 2014; 7():1933-44. PubMed ID: 25364264
[TBL] [Abstract][Full Text] [Related]
6. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
7. 17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion.
Miekus K; Kijowski J; Sekuła M; Majka M
Oncol Rep; 2012 Nov; 28(5):1903-9. PubMed ID: 22941268
[TBL] [Abstract][Full Text] [Related]
8. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
[TBL] [Abstract][Full Text] [Related]
9. Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.
Miranda O; Farooqui M; Siegfried JM
Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30134579
[TBL] [Abstract][Full Text] [Related]
10. Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion.
Náger M; Santacana M; Bhardwaj D; Valls J; Ferrer I; Nogués P; Cantí C; Herreros J
Cell Cycle; 2015; 14(22):3644-55. PubMed ID: 26654598
[TBL] [Abstract][Full Text] [Related]
11. Identification of an EGFRvIII-JNK2-HGF/c-Met-Signaling Axis Required for Intercellular Crosstalk and Glioblastoma Multiforme Cell Invasion.
Saunders VC; Lafitte M; Adrados I; Quereda V; Feurstein D; Ling Y; Fallahi M; Rosenberg LH; Duckett DR
Mol Pharmacol; 2015 Dec; 88(6):962-9. PubMed ID: 26452771
[TBL] [Abstract][Full Text] [Related]
12. Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer.
Sylvester PW
Clin Transl Med; 2014 Dec; 3(1):30. PubMed ID: 26932375
[TBL] [Abstract][Full Text] [Related]
13. The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.
Guo G; Narayan RN; Horton L; Patel TR; Habib AA
Curr Cancer Drug Targets; 2017; 17(3):297-302. PubMed ID: 28004613
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of HGF/MET axis along with p53 inhibition induces de novo glioma formation in mice.
Qin Y; Musket A; Kou J; Preiszner J; Tschida BR; Qin A; Land CA; Staal B; Kang L; Tanner K; Jiang Y; Schweitzer JB; Largaespada DA; Xie Q
Neurooncol Adv; 2020; 2(1):vdaa067. PubMed ID: 32642717
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of miR‑205 is associated with glioblastoma cell migration, invasion, and the epithelial-mesenchymal transition, by targeting ZEB1 via the Akt/mTOR signaling pathway.
Chen W; Kong KK; Xu XK; Chen C; Li H; Wang FY; Peng XF; Zhang Z; Li P; Li JL; Li FC
Int J Oncol; 2018 Feb; 52(2):485-495. PubMed ID: 29345288
[TBL] [Abstract][Full Text] [Related]
16. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy.
Li Y; Guessous F; DiPierro C; Zhang Y; Mudrick T; Fuller L; Johnson E; Marcinkiewicz L; Engelhardt M; Kefas B; Schiff D; Kim J; Abounader R
Mol Cancer Ther; 2009 Feb; 8(2):376-85. PubMed ID: 19190120
[TBL] [Abstract][Full Text] [Related]
17. Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?
Qin A; Musket A; Musich PR; Schweitzer JB; Xie Q
Neurooncol Adv; 2021; 3(1):vdab133. PubMed ID: 34806012
[TBL] [Abstract][Full Text] [Related]
18. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
[TBL] [Abstract][Full Text] [Related]
19. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.
Yap TA; Sandhu SK; Alam SM; de Bono JS
Curr Drug Targets; 2011 Dec; 12(14):2045-58. PubMed ID: 21777195
[TBL] [Abstract][Full Text] [Related]
20. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation.
Lal B; Xia S; Abounader R; Laterra J
Clin Cancer Res; 2005 Jun; 11(12):4479-86. PubMed ID: 15958633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]